On this page

Nystatin

ANDA TE AT Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
NYSTATIN
Generic name
Nystatin
Dosage form
Powder
Route
—
Marketing category
—
Labeler
Antibiotice SA
Product type
Bulk Ingredient
DEA schedule
Not scheduled
Active ingredients
4
NDC product codes
15
Packages
40
Data completeness
82% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Nystatin 1 g/g 261178 View
Nystatin 1 kg/kg 261178 View
Nystatin 100000 [USP'U]/g 261178 View
Nystatin 100000000 [iU]/100000000[iU] 261178 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Powder
Route of administration
—
Presentations
55

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Polyene Antifungal [EPC] EPC All 12 members
Polyenes [CS] CS All 13 members

Regulatory status

Source: Drugs@FDANDC Directory
Application number
208581
Application type
ANDA · Abbreviated New Drug Application
Approval date
June 8, 2017
Sponsor
ZYDUS PHARMS
Products on application
1
Submissions recorded
1
Products approved under application 208581.
Product Trade name Form Strength Ingredient Status TE Flags
208581-001 NYSTATIN POWDER NYSTATIN Prescription AT

Therapeutic equivalence

Source: Orange Book
TE code
AT
Reference Listed Drug
No
Reference Standard
No

What this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 208581.
Type No. Action Status Date Review
Original application 1 Approved June 8, 2017 Standard

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20250930). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20250930 HUMAN PRESCRIPTION DRUG · 20240418

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE Nystatin topical powder is indicated in the treatment of cutaneous or mucocutaneous mycotic infections caused by Candida albicans and other susceptible Candida species . Nystatin topical powder is not indicated for systemic, oral, intravaginal or ophthalmic use.

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION Very moist lesions are best treated with the topical dusting powder. Adults and Pediatric Patients (Neonates and Older): Apply to candidal lesions two or three times daily until healing is complete. For fungal infection of the feet caused by Candida species, the powder should be dusted on the feet, as well as, in all foot wear.

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS Nystatin topical powder is contraindicated in patients with a history of hypersensitivity to any of its components.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS The frequency of adverse events reported in patients using nystatin topical preparations is less than 0.1%. The more common events that were reported include allergic reactions, burning, itching, rash, eczema, and pain on application. (See PRECAUTIONS: General .)

Description

openFDA Drug Labeling

DESCRIPTION Nystatin is a polyene antifungal antibiotic obtained from Streptomyces nursei. The molecular formula for Nystatin is C 47 H 75 NO 17 . The molecular weight of Nystatin is 926.1. Structural formula: Nystatin Topical Powder USP is for dermatologic use. Nystatin Topical Powder USP contains 100,000 USP nystatin units per gram dispersed in talc. Structural Formula

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED Nystatin topical powder is supplied as 100,000 units nystatin per gram in plastic squeeze bottles: 15g (NDC 69315-306-15) 30g (NDC 69315-306-30) 60g (NDC 69315-306-60) STORAGE Store at 20°C to 25°C (68°F to 77°F)[see USP Controlled Room Temperature]; avoid excessive heat (40°C/104°F). Keep tightly closed. Manufactured for: Leading Pharma LLC, Fairfield, NJ 07004 Manufactured by: Lyne Laboratories, Inc. Brockton, MA 02301 R1-01/20

Adverse event reports

Source: openFDA FAERS
27,387
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: NYSTATIN. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
65415-1371-2 65415-1371 Antibiotice SA 16 kg in 1 CARTON (65415-1371-2) March 20, 2014
65415-1372-3 65415-1372 Antibiotice SA 8 kg in 1 CARTON (65415-1372-3) March 20, 2014
68254-2506-1 68254-2506 Concord Biotech Limited 1 BAG in 1 DRUM (68254-2506-1) / 5 kg in 1 BAG October 8, 2024
75907-060-30 75907-060 Dr. Reddy's Labratories Inc. 30 g in 1 BOTTLE, PLASTIC (75907-060-30) May 28, 2024
75907-060-44 75907-060 Dr. Reddy's Labratories Inc. 15 g in 1 BOTTLE, PLASTIC (75907-060-44) May 28, 2024
75907-060-60 75907-060 Dr. Reddy's Labratories Inc. 60 g in 1 BOTTLE, PLASTIC (75907-060-60) May 28, 2024
67630-0016-2 67630-0016 FUJIAN FUKANG PHARMACEUTICAL CO., LTD. 10 kg in 1 DRUM (67630-0016-2) February 13, 2026
67630-0016-6 67630-0016 FUJIAN FUKANG PHARMACEUTICAL CO., LTD. 20 kg in 1 DRUM (67630-0016-6) February 13, 2026
62991-2785-1 62991-2785 LETCO MEDICAL, LLC 100000000 [iU] in 1 JAR (62991-2785-1) June 19, 2009
62991-2785-2 62991-2785 LETCO MEDICAL, LLC 500000000 [iU] in 1 JAR (62991-2785-2) June 19, 2009
62991-2785-3 62991-2785 LETCO MEDICAL, LLC 1000000000 [iU] in 1 JAR (62991-2785-3) June 19, 2009
62991-2785-4 62991-2785 LETCO MEDICAL, LLC 2000000000 [iU] in 1 JAR (62991-2785-4) June 19, 2009
62991-2785-5 62991-2785 LETCO MEDICAL, LLC 5000000000 [iU] in 1 JAR (62991-2785-5) June 19, 2009
62991-2785-6 62991-2785 LETCO MEDICAL, LLC 1500000000 [iU] in 1 PAIL (62991-2785-6) June 19, 2009
69315-306-15 69315-306 Leading Pharma, LLC 15 g in 1 BOTTLE, PLASTIC (69315-306-15) April 23, 2018
69315-306-30 69315-306 Leading Pharma, LLC 30 g in 1 BOTTLE, PLASTIC (69315-306-30) April 23, 2018
69315-306-60 69315-306 Leading Pharma, LLC 60 g in 1 BOTTLE, PLASTIC (69315-306-60) April 23, 2018
38779-0242-0 38779-0242 Medisca Inc. 1538.5 g in 1 PAIL (38779-0242-0) July 16, 2015
38779-0242-1 38779-0242 Medisca Inc. 7.7 g in 1 JAR (38779-0242-1) July 16, 2015
38779-0242-2 38779-0242 Medisca Inc. 23.1 g in 1 JAR (38779-0242-2) July 16, 2015
38779-0242-3 38779-0242 Medisca Inc. 15.5 g in 1 JAR (38779-0242-3) July 16, 2015
38779-0242-5 38779-0242 Medisca Inc. 76.9 g in 1 JAR (38779-0242-5) July 16, 2015
38779-0242-6 38779-0242 Medisca Inc. 153.8 g in 1 JAR (38779-0242-6) July 16, 2015
38779-0242-8 38779-0242 Medisca Inc. 307.7 g in 1 JAR (38779-0242-8) July 16, 2015
38779-0242-9 38779-0242 Medisca Inc. 769.2 g in 1 JAR (38779-0242-9) July 16, 2015
72603-491-01 72603-491 Northstar Rx LLC 15 g in 1 BOTTLE, PLASTIC (72603-491-01) September 1, 2025
72603-491-02 72603-491 Northstar Rx LLC 30 g in 1 BOTTLE, PLASTIC (72603-491-02) September 1, 2025
72603-491-03 72603-491 Northstar Rx LLC 60 g in 1 BOTTLE, PLASTIC (72603-491-03) September 1, 2025
17337-0330-0 17337-0330 Olon S.p.A. 16.84 kg in 1 BOX (17337-0330-0) February 15, 2024
17337-0331-0 17337-0331 Olon S.p.A. 12.15 kg in 1 BOX (17337-0331-0) February 15, 2024
51927-0095-0 51927-0095 Professional Compounding Centers of America 1 kg in 1 BOTTLE (51927-0095-0) May 3, 2021
53734-336-01 53734-336 VUAB Pharma A.S. 1.55 kg in 1 CONTAINER (53734-336-01) August 10, 2017
53734-336-02 53734-336 VUAB Pharma A.S. 8 kg in 1 CONTAINER (53734-336-02) August 10, 2017
53734-336-03 53734-336 VUAB Pharma A.S. 15.5 kg in 1 CONTAINER (53734-336-03) August 10, 2017
70771-1585-1 70771-1585 Zydus Lifesciences Limited 15 g in 1 BOTTLE, PLASTIC (70771-1585-1) October 6, 2021
70771-1585-2 70771-1585 Zydus Lifesciences Limited 30 g in 1 BOTTLE, PLASTIC (70771-1585-2) October 6, 2021
70771-1585-3 70771-1585 Zydus Lifesciences Limited 60 g in 1 BOTTLE, PLASTIC (70771-1585-3) October 6, 2021
68382-370-01 68382-370 Zydus Pharmaceuticals USA Inc. 15 g in 1 BOTTLE, PLASTIC (68382-370-01) October 6, 2021
68382-370-02 68382-370 Zydus Pharmaceuticals USA Inc. 30 g in 1 BOTTLE, PLASTIC (68382-370-02) October 6, 2021
68382-370-03 68382-370 Zydus Pharmaceuticals USA Inc. 60 g in 1 BOTTLE, PLASTIC (68382-370-03) October 6, 2021
65415-1371 65415-1371 Antibiotice SA — March 20, 2014
65415-1372 65415-1372 Antibiotice SA — March 20, 2014
68254-2506 68254-2506 Concord Biotech Limited — October 8, 2023
75907-060 75907-060 Dr. Reddy's Labratories Inc. — May 28, 2024
67630-0016 67630-0016 FUJIAN FUKANG PHARMACEUTICAL CO., LTD. — February 13, 2026
62991-2785 62991-2785 LETCO MEDICAL, LLC — June 19, 2009
69315-306 69315-306 Leading Pharma, LLC — April 23, 2018
38779-0242 38779-0242 Medisca Inc. — July 16, 2015
72603-491 72603-491 Northstar Rx LLC — September 1, 2025
17337-0330 17337-0330 Olon S.p.A. — February 15, 2024
17337-0331 17337-0331 Olon S.p.A. — February 15, 2024
51927-0095 51927-0095 Professional Compounding Centers of America — May 3, 2021
53734-336 53734-336 VUAB Pharma A.S. — August 10, 2017
70771-1585 70771-1585 Zydus Lifesciences Limited — October 6, 2021
68382-370 68382-370 Zydus Pharmaceuticals USA Inc. — October 6, 2021

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts

Generated September 25, 2026 · 12 sections on this page.